A Possible Bidding War for Human Genome Sciences?

Source: Seeking Alpha (7/9/12)

"Human Genome has set a July 16 deadline for takeover offers from suitors other than GlaxoSmithKline. Investors would likely react with horror and anger if Celgene were to make a run at Human Genome."

Seeking Alpha

Reuters announced late Friday, July 6, 2012, that an unnamed source said Celgene (CELG) may be mulling a bid for Human Genome Science, Inc. (HGSI). Late Sunday, July 8, 2012, The Street, also referencing an unnamed source, wrote, "Celgene has no interest in an acquisition of Human Genome or a merger of equals between the two companies, according to my source, contradicting the Reuters story. More likely, bankers working for Human Genome are planting speculative rumors in the press to compel Glaxo to raise its offer price, my source adds.". . .View Full Article

Biopharma Reaches 50% Enrollment in New ALS Drug Program
Source: Jason Kolbert (02/02/2026)

MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm.

Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study
Source: Streetwise Reports (02/02/2026)

Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year.

Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market
Source: Streetwise Reports (01/30/2026)

Biopharmaceutical firm MediciNova Inc. (MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year.

Report of FDA Drug Approval Delay is 'Likely Noise': Analyst
Source: Douglas Tsao (01/27/2026)

Disc Medicine Inc.'s (IRON:NASDAQ) chances of bitopertin getting approved remain unaltered by the claims in a recent article, noted an H.C. Wainwright & Co. report. Read on to learn the reasons behind this opinion of the investment bank.

AI Collaboration Expands to Accelerate Cancer Drug Discovery
Source: Streetwise Reports (01/12/2026)

Rakovina Therapeutics Inc. (RKV:TSX.V) has broadened its partnership with Variational AI to refine next-generation ATR inhibitors using generative AI. The agreement aims to streamline lead optimization for the company's kt-5000 series of small-molecule cancer drug candidates.